Phase 1 Clinical Trials for Healthy Volunteers
First-in-human drug safety and dosing studies that compensate healthy adults.
There are 440 actively recruiting Phase 1 clinical trials enrolling healthy volunteers. Phase 1 studies test investigational drugs for safety and dosing in small groups under close medical supervision. Updated daily from ClinicalTrials.gov.
What is a Phase 1 trial?
Phase 1 is the first stage of human testing. A small group of healthy volunteers receives the investigational drug to evaluate safety, tolerability, and pharmacokinetics. Participants are monitored closely — often as inpatients at a clinical pharmacology unit — and compensated for their time. These studies are reviewed and approved by an ethics committee before enrollment begins.
Showing 161–180 of 440 Phase 1 studies
To studyJUV-161 Administered to Healthy Volunteers Undergoing Unilateral Lower Limb Immobilization (ULLI)
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants
A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants
Comparative Analysis of Biotinylated, Irradiated and 51-Chromium Radiolabeled Red Blood Cells for Analysis of Recovery and Survival After Autologous Transfusion
A Study of ORN252 in Healthy Participants
A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.
A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Study of BW-50218 in Healthy Participants
A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Dextromethorphan (CYP2D6 Substrate) in Healthy Participants
A Study to Evaluate Single and Multiple Doses of TLC-1180 in Healthy Subjects
Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]GRT6019
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SV003 in Healthy Participants.
Single Ascending Dose Study of HB2198 in Healthy Participants
SAD and MAD Study of AKB-9090 in Healthy Adult Participants
Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants
A Study of the Effect of Diltiazem on the Plasma Levels of Nemtabrutinib (MK-1026-022)
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
A Study of [14C]-LY4064809 in Healthy Participants
Phase 1 FAQ
How much do Phase 1 trials pay?
Compensation varies by study duration and intensity. Inpatient Phase 1 studies (multi-day residential stays) typically pay $1,000–$5,000+. Outpatient studies with follow-up visits may pay $200–$1,500. Specific amounts are disclosed in the informed consent document.
Are Phase 1 trials safe?
Phase 1 trials carry some risk as participants receive an investigational drug. All studies are reviewed and approved by an ethics committee (IRB/HREC) before enrollment begins. Participants are monitored continuously and can withdraw at any time.
What happens during a Phase 1 study?
Typically you attend a screening visit, then either stay at the clinical unit (inpatient) or visit regularly (outpatient). Blood draws, vital signs, and other assessments are conducted at scheduled intervals. The study team monitors you throughout and provides meals and accommodation for inpatient stays.